Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENLVNASDAQ:ONTXNASDAQ:TRVNNASDAQ:VBLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$1.45-3.3%$3.22$1.15▼$4.59$26.93M1.02161,377 shs52,532 shsONTXOnconova Therapeutics$0.84$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsTRVNTrevena$0.41+7.3%$0.49$0.30▼$3.28$7.49M1.1180,896 shs114,785 shsVBLTVascular Biogenics$5.46-8.8%$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics+13.64%+1.35%-63.50%-48.28%-46.24%ONTXOnconova Therapeutics0.00%0.00%+13.36%+47.89%-15.65%TRVNTrevena-1.80%-4.32%-12.41%-40.86%-39.04%VBLTVascular Biogenics0.00%0.00%0.00%0.00%+3,207.09%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENLVEnlivex Therapeutics2.3396 of 5 stars3.53.00.00.01.90.81.3ONTXOnconova Therapeutics0.7261 of 5 stars3.53.00.00.00.00.00.0TRVNTrevena2.5298 of 5 stars3.55.00.00.02.50.00.6VBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics3.00Buy$7.00382.76% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideTRVNTrevena3.00Buy$9.002,100.49% UpsideVBLTVascular BiogenicsN/AN/AN/AN/ACurrent Analyst RatingsLatest VBLT, ENLV, ONTX, and TRVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.004/12/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.004/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00TRVNTrevena$3.12M2.40N/AN/A($0.44) per share-0.93VBLTVascular Biogenics$660K642.29N/AN/A$0.32 per share17.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics-$29.07M-$1.56N/AN/AN/AN/A-71.00%-59.08%6/21/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)TRVNTrevena-$40.29M-$3.13N/AN/AN/AN/A-1,018.15%-98.93%5/20/2024 (Estimated)VBLTVascular Biogenics-$32.30M-$0.21N/A∞N/AN/A-73.45%-54.11%N/ALatest VBLT, ENLV, ONTX, and TRVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023TRVNTrevenaN/A-$1.06-$1.06-$1.06$0.09 million($0.08) million3/29/2024Q4 2023ENLVEnlivex TherapeuticsN/A-$0.48-$0.48-$0.48N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A5.577.34ONTXOnconova TherapeuticsN/A2.792.79TRVNTrevena8.354.664.66VBLTVascular BiogenicsN/A4.634.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%ONTXOnconova Therapeutics7.95%TRVNTrevena13.56%VBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%ONTXOnconova Therapeutics3.30%TRVNTrevena2.40%VBLTVascular Biogenics6.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics5018.57 million16.29 millionOptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableTRVNTrevena2318.32 million17.88 millionOptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableVBLT, ENLV, ONTX, and TRVN HeadlinesSourceHeadlineTommy Garten elected to VBL Hall of Fametherecorderonline.com - March 28 at 1:31 PMControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemnature.com - February 21 at 3:29 PMVascular News and Researchnews-medical.net - November 25 at 2:28 PMVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26msn.com - November 3 at 12:39 AMNotable Labs Closes Merger Transaction With VBL Therapeuticsfinance.yahoo.com - October 16 at 3:55 PMVBL Therapeutics Announces Results of Annual and Special Shareholder Meetingfinance.yahoo.com - October 12 at 3:13 PMVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meetingfinance.yahoo.com - October 4 at 8:40 AMVascular Biogenics Rises on Presentation Hypefinance.yahoo.com - September 9 at 12:00 PMVBLT Stock Sees Decline of Approximately -0.22% in Last Five Daysknoxdaily.com - September 7 at 9:15 PMVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECfinance.yahoo.com - September 6 at 7:30 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 7:00 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 3:04 PMVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 8:09 AMMonitoring Vascular Biogenics Ltd. (VBLT) after recent insider movementsknoxdaily.com - July 26 at 4:10 PMVascular Biogenics (NASDAQ: VBLT)fool.com - July 23 at 5:52 PMRecent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)knoxdaily.com - July 12 at 4:20 PMVBLT Stock Sees Decline of Approximately -4.31% in Last Five Daysknoxdaily.com - July 7 at 2:11 PMDays-to-cover ratio for VBLT surges to 0.84 due to rise in short interestknoxdaily.com - June 23 at 8:26 PMThe Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgerymedscape.com - May 18 at 1:35 AMVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 8:03 PMDeveloping a Patient-Centered Approach to Vascular Access Device Selectionmedscape.com - May 10 at 8:52 AMCADASIL: The Most Common Hereditary Subcortical Vascular Dementiamedscape.com - May 5 at 1:05 AMAspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Diseasemedscape.com - May 2 at 8:00 PMVascular Biogenics Stock (NASDAQ:VBLT), Dividendsbenzinga.com - April 4 at 1:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEnlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Vascular BiogenicsNASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.